HIV

The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.

Latest News

Illicit drugs | Image credit: Stanislau_V - stock.adobe.com
SDOH Domains at Risk Correlated With Substance Use in People With HIV

May 2nd 2025

Correlation to social drivers of health (SDOH) had an important correlation with polysubstance use.

HIV | Image credit: reddish - stock.adobe.com
Family Dynamics, Mental Health Influence Adherence to ART

April 29th 2025

Richard Hughes IV, JD, MPH
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV

April 21st 2025

Women with HIV | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
Poor Well-Being in HIV Associated With SDOH Adversities

April 16th 2025

Money | Image credit: Stillfx - stock.adobe.com
Freeze in International Funding Could Significantly Reverse Progress in HIV Treatment

April 3rd 2025

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.
Continuing Medical Education
View All
May 2nd 2025

Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence

1.5 Credits / HIV/AIDS, Infectious Diseases

More News

Evolocumab Lowers LDL-C in HIV-Positive Persons
March 31st 2020

Evolocumab Lowers LDL-C in HIV-Positive Persons

Maggie L. Shaw
Evolocumab (Repatha), a human monoclonal antibody and proprotein convertase subtilisin/kexin type 9 inhibitor, produced positive results in persons living with HIV in the BEIJERINCK study by reducing their levels of low-density lipoprotein cholesterol (LDL-C). These individuals have a risk of cardiovascular disease that is almost twice that of HIV-negative individuals.
COVID-19 Questions HIV-Positive Individuals Want Answered
March 24th 2020

COVID-19 Questions HIV-Positive Individuals Want Answered

Maggie L. Shaw
The environment surrounding the coronavirus disease 2019 (COVID-19) pandemic seems to change by the minute. The full extent to which HIV-positive individuals can be affected if they contract COVID-19, because they are immunocompromised, is not known. Recently, the CDC issued guidance for this patient population.
Study Results Recommend Ongoing, but Updated, HIV-1/HIV-2 Differentiation Testing
March 20th 2020

Study Results Recommend Ongoing, but Updated, HIV-1/HIV-2 Differentiation Testing

Maggie L. Shaw
Between 2010 and 2017, there were 327,700 new HIV infections in the United States. Of these, HIV-2 infections accounted for less than 0.03% of the total. It is important to differentiate which HIV strain an individual is infected with because HIV-2 is intrinsically resistant to nonnucleoside reverse-transcriptase inhibitors, which are typically used to treat HIV-1 infections.
People With HIV at a Higher Risk of Cardiovascular Diseases, Study Finds
March 16th 2020

People With HIV at a Higher Risk of Cardiovascular Diseases, Study Finds

Alison Rodriguez
The association of HIV infection with cardiovascular disease was particularly strong for heart failure and stroke.
Questions Remain About Second Patient Who Demonstrates HIV Cure
March 10th 2020

Questions Remain About Second Patient Who Demonstrates HIV Cure

Maggie L. Shaw
A second individual may have been cured of HIV following an allogeneic stem-cell transplant for stage 4b refractory Hodgkin lymphoma with Δ32-mutated cells, which are resistant to the virus. These cells did not express the CCR5 chemokine receptor, 1 of 2 methods of entry for HIV into a host cell.
What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab
March 9th 2020

What We're Reading: Second Person Cured of HIV Speaks Out; BMS' MM Therapy Fails Study; FDA to Review Biosimilar Bevacizumab

AJMC Staff
A year after being only the second person to be cured of HIV, the “London Patient” revealed his identity; BMS announced today that its combination therapy for multiple myeloma—elotuzumab, lenalidomide, and dexamethasone—failed its primary endpoint of progression-free survival in its phase 3 ELOQUENT-1 trial; Biocon and Mylan N.V. announced that the FDA accepted their biologics license application (BLA) for MYL-14020, a proposed biosimilar to bevacizumab (Avastin), for review.
Next-Generation Sequencing Used to Characterize HIV Epidemic in Washington, DC
March 2nd 2020

Next-Generation Sequencing Used to Characterize HIV Epidemic in Washington, DC

Gianna Melillo
In 2018, Washington, DC, saw 340 newly diagnosed cases of HIV, according to a study published in Scientific Reports. The city’s rate is 5 times higher than the national rate, and it falls under the World Health Organization’s definition of an epidemic. Researchers used next-generation sequencing to gain a broader view of the disease’s dynamics in the DC area.
COPD Is a More Likely Comorbid Condition in HIV-Positive Individuals
February 29th 2020

COPD Is a More Likely Comorbid Condition in HIV-Positive Individuals

Maggie L. Shaw
Chronic obstructive pulmonary disease (COPD) occurs at a higher rate in individuals who have HIV compared with those who do not, and it has a global incidence of more than 380 million people. The progressive lung disease is also diagnosed at a younger age in HIV-positive persons compared with their HIV-negative counterparts, and higher rates of smoking may be to blame.
What We're Reading: Florida Doctor Stole Millions; Rural Areas and HIV Risk; Disposable Vapes Replace Juul
February 18th 2020

What We're Reading: Florida Doctor Stole Millions; Rural Areas and HIV Risk; Disposable Vapes Replace Juul

AJMC Staff
A vascular surgeon in Florida allegedly stole $26 million from insurers and the government; a new report finds many rural areas are still at risk of an HIV outbreak; new disposable flavored vape pens have largely replaced Juul use among teens.
Youth Newly Diagnosed With HIV Have Advanced Infection, Higher Viral Loads
February 18th 2020

Youth Newly Diagnosed With HIV Have Advanced Infection, Higher Viral Loads

Maggie L. Shaw
Close to 80% of HIV-positive individuals are shown to be virally suppressed through their most recent test results, according to data from 2016 through 2018, as well as 32% to 63% of adults older than 24 years. Youth with a new HIV diagnosis, however, come in at only 12%.
What Can Be Done to Improve the HIV Testing Rate of At-Risk Teenage Boys?
February 11th 2020

What Can Be Done to Improve the HIV Testing Rate of At-Risk Teenage Boys?

Maggie L. Shaw
Among the general population of the United States, 14.5% of HIV-positive individuals do not know their disease status. This rate increases to 51.5% of 13- to 24-year-olds, among whom men who have sex with men account for 80% of new HIV infections.
Enrollment in AIDS Drug Assistance Programs Linked With Viral Suppression, Study Finds
February 10th 2020

Enrollment in AIDS Drug Assistance Programs Linked With Viral Suppression, Study Finds

Alison Rodriguez
Enrollment in AIDS Drug Assistance Programs (ADAPs)–funded Qualified Health Plans (QHPs) is associated with viral suppression (VS) across states and demographic groups. People living with HIV who engage in care and have QHPs have a higher VS rate than those who received medications from direct ADAPs.
What We're Reading: Gilead Dealt Patent Setback; Merck Spins Off Businesses; Governors' Medicaid Worries
February 6th 2020

What We're Reading: Gilead Dealt Patent Setback; Merck Spins Off Businesses; Governors' Medicaid Worries

AJMC Staff
The Patent Trial and Appeals Board delivered a setback to Gilead Sciences, rejecting its attempt to invalidate a pair of Truvada patents owned by the CDC; Merck is spinning off some businesses in order to focus on its oncology drug pembrolizumab, including its biosimilars operations; Republican and Democratic governors are worried that a proposed CMS fiscal accountability rule for Medicaid will reduce access to healthcare.
What We're Reading: FDA Launches HIV Drug Database; HIV Vaccine Trial Fails; NJ Enacts Coronavirus Task Force
February 4th 2020

What We're Reading: FDA Launches HIV Drug Database; HIV Vaccine Trial Fails; NJ Enacts Coronavirus Task Force

AJMC Staff
The FDA launched a mobile-friendly, interactive database providing information on eligible HIV antiretroviral treatments available; an HIV vaccine trial by Fred Hutchinson Cancer Research Center ended after failing to provide protection from the virus; New Jersey Governor Phil Murphy established a coronavirus task force to manage the state’s preparedness and response to the virus.
What Is the True Cost of the High Price of ART?
February 3rd 2020

What Is the True Cost of the High Price of ART?

Maggie L. Shaw
Antiretroviral treatment (ART) is the regimen mainstay for everyone who has HIV, irrespective of infection duration. More than twice as many options for ART were available in 2018 as were offered in 2012—but this did not equal cheaper prices. Between 2012 and 2018, the average wholesale price for initial ART jumped 34% for most people with HIV.
Study Finds Discrepancies From Guidelines in Prescribing Practices for Pregnant Women Living With HIV
February 2nd 2020

Study Finds Discrepancies From Guidelines in Prescribing Practices for Pregnant Women Living With HIV

Alison Rodriguez
The authors noted that pregnant women are typically excluded from clinical trials investigating the safety and tolerability of HIV medications.
Innovative Research Program Provides Deeper Understanding of HIV's Dynamic Process
January 28th 2020

Innovative Research Program Provides Deeper Understanding of HIV's Dynamic Process

Maggie L. Shaw
Participants in Last Gift, an end-of-life HIV research program from UC San Diego, donate their blood and their bodies so researchers can uncover all the places that HIV hides, to both fight the disease and stop it. Before each autopsy, the following is read: “From our first breath to our last, each of us tells a unique story. Here, we honor our Last Gift participants for their altruism to further research into HIV and the human condition. We take this moment of silence to honor their gifts and express our gratitude for all the discoveries their selfless donations will yield.”
NY Attorney General, Federal Trade Commission Sue Martin Shkreli
January 28th 2020

NY Attorney General, Federal Trade Commission Sue Martin Shkreli

Gianna Melillo
New York Attorney General Letitia James announced a lawsuit filed against 2 former chief executive officers of Turing Pharmaceuticals, now known as Vyera Pharmaceuticals: “Pharma Bro” Martin Shkreli, currently serving a 7-year sentence in federal prison for securities fraud, a crime that took place before the launch of Vyera, and his business partner Kevin Mulleady.
What We're Reading: HIV Drug Tested in Treating Coronavirus; Preterm Birth Drug Debate; Trump Threatens Funds to California
January 27th 2020

What We're Reading: HIV Drug Tested in Treating Coronavirus; Preterm Birth Drug Debate; Trump Threatens Funds to California

AJMC Staff
Chinese health authorities are testing an HIV drug, lopinavir and ritonavir, as a potential treatment for the new coronavirus; a debate is growing over the efficacy of the sole drug approved to prevent preterm birth; the Trump administration threatens to withhold Califonia’s federal funding due to its abortion coverage requirements.
Subset of T Cells Has Specialized Role in Early Stages of HIV, Researchers Determine
January 22nd 2020

Subset of T Cells Has Specialized Role in Early Stages of HIV, Researchers Determine

Maggie L. Shaw
Mucosa-associated invariant T cells (MAIT cells) are a subset of the T-cell population. Their function and activity during the acute stage of HIV infection adds to the knowledge of immune system activation at this stage and could lead to possible new treatment interventions.
In Debate Over PrEP, Researchers Raise Questions About Benefit vs Value
January 14th 2020

In Debate Over PrEP, Researchers Raise Questions About Benefit vs Value

Maggie L. Shaw
Truvada and Descovy are both manufactured by Gilead Sciences and used to treat HIV-1 infection and as pre-exposure prophylaxis (PrEP) in adult and pediatric patients.
Cancer Immunotherapy Likely Safe, Effective for Those With HIV, Other Infections, Study Suggests
January 12th 2020

Cancer Immunotherapy Likely Safe, Effective for Those With HIV, Other Infections, Study Suggests

Sara Karlovitch
Although the researchers state that more studies are needed to validate their findings, they found that patients who also had HIV, HBV, or HCV who were being treated with ICI therapy had similar rates of efficacy and toxicity to patients without chronic viral infections.
Death Anxiety, Social Support Among Persons Living With HIV, AIDS in Nigeria
January 11th 2020

Death Anxiety, Social Support Among Persons Living With HIV, AIDS in Nigeria

Maggie L. Shaw
Nigeria has a population of almost 204 million. Of those, 3.1% of adults, or 3.5 million, are living with HIV. The accompanying death anxiety of people living with HIV and AIDS has not been studied in depth.
Understanding Why HIV-Positive Individuals Would, or Would Not, Risk Their Lives for a Cure
December 29th 2019

Understanding Why HIV-Positive Individuals Would, or Would Not, Risk Their Lives for a Cure

Maggie L. Shaw
There are 12 clinical trials underway investigating various combination treatments for HIV and AIDS, but a cure remains elusive. Few studies have attempted to qualify and quantify the risk HIV-positive individuals claim they would take if it meant a cure could result.
CDC Report Looks at Nonadherence to HIV Medications Due to Cost
December 28th 2019

CDC Report Looks at Nonadherence to HIV Medications Due to Cost

Alison Rodriguez
The report suggests that removing barriers to coverage, as well as reducing medication costs for people with private insurance, would help decrease cost-related nonadherence to HIV therapies.
Researchers Report New Insights Into HIV-Related Neurocognitive Disorders
December 25th 2019

Researchers Report New Insights Into HIV-Related Neurocognitive Disorders

AJMC Staff
The use of antiretroviral therapy has allowed patients with HIV to have a life expectancy that approaches the lifespan of those without HIV. Despite this progress, however, HIV-associated neurocognitive disorders remain prevalent, and range from mild problems with memory, language, and reasoning to more severe HIV-associated dementia.
Treating HIV Comorbidities in the Fight to End the Epidemic
December 16th 2019

Treating HIV Comorbidities in the Fight to End the Epidemic

Maggie L. Shaw
HIV-positive individuals face greater risks of kidney and liver diseases, cardiovascular events, osteoporosis, hepatitis C, and cancer. Clinical trials and research advances into the cause and development of the comorbid conditions are needed.
People With HIV/AIDS at Greater Risk for Chronic Illnesses, Study Finds
December 15th 2019

People With HIV/AIDS at Greater Risk for Chronic Illnesses, Study Finds

Alison Rodriguez
People living with HIV/AIDS (PLWHA) may be at a greater risk for a variety of chronic illnesses and may require additional care as the older PLWHA population increases, a recent study suggested.
Administering ART Immediately After Birth Triggers Innate Immune Response, HIV Reservoir Shrinkage in Infants Born With HIV
December 12th 2019

Administering ART Immediately After Birth Triggers Innate Immune Response, HIV Reservoir Shrinkage in Infants Born With HIV

Maggie L. Shaw
A second study, slated for next year, will continue these infants on antiretroviral treatment with 2 experimental monoclonal antibodies, hoping the medications produce viral suppression—and testing the effects of temporarily stopping them—so that they don’t have to eventually initiate the standard triplet therapy that most older patients typically take. For adults, most treatments for HIV come from the cancer field, and are inflammatory, and are not safe enough to apply in children. An ongoing debate is when is it appropriate to begin these therapies in children.
Site Logo
December 10th 2019

Clinical Characteristics and Treatment Patterns Among US Patients With HIV

Julie L. Priest, MSPH Tanya Burton, PhD Cori Blauer-Peterson, MPH Kate Andrade, MPH Alan Oglesby, MPH
It is important to take into account individual complexities such as comorbidities and pill burden when selecting antiretroviral therapy regimens for individuals living with HIV.
<1
...
141516171819202122
...
32>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo